Cargando…

COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study

Background: Vaccination has been effective in preventing COVID-19 infections and related mortality. However, waning immunity after two-dose vaccination prompted health authorities to recommend a third dose of COVID-19 vaccine to boost immunity. The aim of our study was to assess willingness to recei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shehab, Mohammad, Alrashed, Fatema, Alfadhli, Ahmad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331669/ https://www.ncbi.nlm.nih.gov/pubmed/35893815 http://dx.doi.org/10.3390/vaccines10081166

Ejemplares similares

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)
por: Alrashed, Fatema, et al.
Publicado: (2023)

Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study
por: Shehab, Mohammad, et al.
Publicado: (2022)

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
por: Shehab, Mohammad, et al.
Publicado: (2021)

Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study
por: Shehab, Mohammad, et al.
Publicado: (2023)

Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study
por: Shehab, Mohammad, et al.
Publicado: (2022)

COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study
por: Shehab, Mohammad, et al.
Publicado: (2021)

The Role of Clinical Pharmacists in Improving Quality of Care in Patients with Inflammatory Bowel Disease: An Evaluation of Patients’ and Physicians’ Satisfaction
por: Alrashed, Fatema, et al.
Publicado: (2022)

Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab
por: Loveikyte, Roberta, et al.
Publicado: (2023)

Impact of biologics and small molecules for inflammatory bowel disease on COVID‐19‐related hospitalization and mortality: A systematic review and meta‐analysis
por: Alrashed, Fatema, et al.
Publicado: (2022)

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
por: Lin, Simeng, et al.
Publicado: (2022)

Willingness to pay for and willingness to vaccinate with the COVID-19 vaccine booster dose in China
por: Zhou, Hui Jun, et al.
Publicado: (2022)

Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
por: Remy, Clotilde, et al.
Publicado: (2022)

Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis
por: Alrashed, Fatema, et al.
Publicado: (2021)

Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
por: Shehab, Mohammad, et al.
Publicado: (2021)

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2022)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland
por: Rzymski, Piotr, et al.
Publicado: (2021)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study
por: Veisman, Ido, et al.
Publicado: (2021)

Willingness and Perceptions Regarding COVID-19 Vaccine Booster Dose in Pakistani Vaccinated Population: A Cross-Sectional Survey
por: Moeed, Abdul, et al.
Publicado: (2022)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)

Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
por: Saad Alshahrani, Abdulaziz, et al.
Publicado: (2023)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
por: Kaneoka, Ayaka, et al.
Publicado: (2022)

Biologic Therapies for the Treatment of Post-ileal Pouch Anal Anastomosis Surgery Chronic Inflammatory Disorders: Systematic Review and Meta-analysis
por: Shehab, Mohammad, et al.
Publicado: (2022)

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
por: Krupka, Niklas, et al.
Publicado: (2014)

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
por: Fleisher, Mark, et al.
Publicado: (2018)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

Is Vedolizumab Truly Gut Selective? It May Not Affect the Immunogenicity of Vaccines in Patients With Inflammatory Bowel Disease
por: Lee, Alexander S, et al.
Publicado: (2020)

The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab
por: Harrington, Jill E, et al.
Publicado: (2020)

Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center
por: Allamneni, Chaitanya, et al.
Publicado: (2018)

Infliximab/vedolizumab: Drug-induced lupus, pneumonitis and lack of efficacy: case report
Publicado: (2021)

Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
por: Lynch, Kate D., et al.
Publicado: (2020)

Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience
por: Erdoğan, Çağdaş, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jvkvkfdq29g0licvicjvnudoj7